Clinical Trials Sponsored by HAL Allergy

Total 5906 results

HAL Allergy

Completed

HAL-MPE1 First-in-human (HAL-MPE1/0043)

Peanut Allergy

Denmark
HAL Allergy

Completed

SUBLIVAC® Birch PROBE Study

Birch Pollen Allergy | Seasonal Rhinitis and/or Rhinoconjunctivitis

Germany
HAL Allergy

Completed

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany
HAL Allergy

Completed

HAL-MPE1 Safety and Tolerability Study

Peanut Allergy

United States, Canada
HAL Allergy

Completed

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Belgium, Germany, Austria, Netherlands, Spain
HAL Allergy

Completed

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Poland, Czech Republic, Germany
HAL Allergy

Completed

Twin SUBLIVAC® Grasses Clinical Efficacy Study

Rhinitis, Allergic, Seasonal | Conjunctivitis, Allergic

Germany, Poland, Belgium, Netherlands
HAL Allergy

Completed

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Canada
HAL Allergy

Completed

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Rhinitis, Allergic | Rhinoconjunctivitis, Allergic

Canada
HAL Allergy

Completed

SUBLIVAC FIX Birch Phase III Short-term Efficacy

Birch Pollen Induced Rhinitis/Rhinoconjunctivitis

Belgium, Germany, Czech Republic, Poland, Slovakia
HAL Allergy

Completed

SUBLIVAC FIX Mite Mixture Dose Tolerability Study (DTS)

House Dust Mite Allergy

Germany
HAL Allergy

Completed

SUBLIVAC FIX Phleum Pratense DT/DRF

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany, Poland
HAL Allergy

Completed

PURETHAL Grasses Rush Study

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Germany
HAL Allergy
Ergomed

Completed

PURETHAL Birch RUSH Study

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Poland
Allergy Therapeutics
Bencard Allergie GmbH

Active, not recruiting

Tyrosine Allergoid Paediatric and Adult Study

Allergic Conjunctivitis | Allergic Asthma | Allergic Rhinitis Due to Pollen

Germany
Allergy Therapeutics
Ecarf Institute GmbH; Bencard Allergie GmbH

Completed

Effect of holoBLG on Cat Allergic Patients

Allergic Rhinoconjunctivitis | Allergy to Cats

Germany
Hal C Charles

Completed

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

Asthma | Emphysema | Cystic Fibrosis | COPD | Small Airways Diseases

United States
Emad Abdel Aal Saliem

Completed

Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery

Pharmacological Action

Egypt
Hal C Charles

Completed

19F Thoracic Radiotherapy for Lung Cancer

Lung Cancer

United States
Hal C Charles

Withdrawn

Comparison of 133Xe Scintigraphy With 19F MRI

Lung Diseases

United States
Hal C Charles

Completed

Imaging Regional Lung Defect Severity (DIAL1001004)

COPD

United States
Hal C Charles

Completed

Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)

Constrictive Bronchiolitis | Iraq-Afganistan War Lung Injury Syndrome

United States
Hal C Charles

Completed

Lung Transplant Subjects Using 19F MRI (DIAL1001005)

Post Single or Double Lung Transplant

United States
Hal C Charles

Completed

Imaging Lung Function Using Oxygen Enhanced MRI

Asthma | Emphysema | Cystic Fibrosis | COPD | Small Airways Disease

United States
National Institute of Allergy and Infectious Diseases...
Allergan

Withdrawn

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV Infections
Isabel Moreno Hay
Allergan Sales, LLC

Recruiting

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

Neuropathic Pain

United States
Allergy Therapeutics

Completed

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Seasonal Allergic Rhinitis | Rhinoconjunctivitis

United States, Germany, Austria, Hungary, Czechia, Poland
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Allergy Therapeutics

Recruiting

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects (PROTECT)

Peanut Allergy

United States
Allergy Therapeutics

Completed

An Exploratory Study of PQ Grass 27600 SU

Rhinitis, Allergic, Seasonal

United States, Germany
Allergy Therapeutics

Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Seasonal Allergic Rhinitis

United States
Allergy Therapeutics

Terminated

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Respiratory Tract Infections | Allergy | Rhinitis, Allergic | Allergic Conjunctivitis | Allergic Asthma

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
HALO Diagnostics
HALO Affiliate Sites

Recruiting

Phase I Human Analytics (HALO) Study (HALO)

Cardiovascular Diseases | Cancer | Dementia | Traumatic Brain Injury

United States
Hamilton Health Sciences Corporation
AllerGen NCE Inc.; Food Allergy Initiative

Unknown

Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut

Peanut Hypersensitivity

Canada

Clinical Trials Sponsored by HAL Allergy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations